Halothane Chemical Properties

Melting point:

-115.75°C

Boiling point:

50.2 °C(lit.)

Density 

1.872 g/mL at 25 °C(lit.)

vapor pressure 

4.5 psi ( 20 °C)

refractive index 

n20/D 1.369(lit.)

Flash point:

49-50°C

storage temp. 

2-8°C

solubility 

Slightly soluble in water, miscible with anhydrous ethanol and with trichloroethylene.

form 

Colorless liquid

color 

Colorless to light yellow

Water Solubility 

Soluble in water (8 mg/ml).

Sensitive 

Light Sensitive

Merck 

14,4603

BRN 

1736947

Exposure limits

TLV-TWA 50 ppm (～400 mg/m³) (ACGIH).

CAS DataBase Reference

151-67-7(CAS DataBase Reference)

EPA Substance Registry System

Halothane (151-67-7)

Safety Information

Hazard Codes 

T,Xi,Xn

Risk Statements 

61-37/38-41-40-20

Safety Statements 

53-23-26-36/37-45-36

RIDADR 

UN 3334

OEL

Ceiling: 2 ppm (16.2 mg/m3) [60-minute] [*Note: REL for exposure to waste anesthetic gas.]

WGK Germany 

3

RTECS 

KH6550000

F 

8-19

Hazard Note 

Irritant

HS Code 

2937990000

Hazardous Substances Data

151-67-7(Hazardous Substances Data)

Toxicity

LD50 oral in rat: 5680mg/kg

MSDS

• Language:English Provider:SigmaAldrich
• Language:English Provider:ALFA

Halothane Usage And Synthesis

Description

Halothane was introduced into medical practice in the United States in 1956 as a nonflammable, nonexplosive, halogenated volatile anesthetic that usually is mixed with air or oxygen. The presence of the carbon–halogen bonds contributes to its nonflammability. This clear liquid with a sweet odor was developed based on predictions that its halogenated structure would provide chemical stability, an intermediate blood solubility, and significant anesthetic potency. Halothane is the only useful volatile anesthetic possessing a bromine atom, which has been suggested to contribute to its potency. Similarly, the addition of fluorine atoms, of which halothane has three, is thought to contribute to the increased potency, volatility, and increased chemical stability of the hydrocarbon skeleton.
Halothane produces rapid onset and recovery from anesthesia with high potency when used alone or in combination with nitrous oxide. Most metals, with the exception of chromium, nickel, and titanium, are easily tarnished by halothane. Although halothane is relatively stable, it is subject to spontaneous oxidative decomposition to hydrochloric acid, hydrobromic acid, and phosgene. For this reason, it is available in dark, amber glass containers with thymol added as a preservative to minimize decomposition. Halothane may permeate into the rubber components of the anesthetic delivery devices, which might account for some slowing of the induction onset and recovery. Approximately 20% of an administered dose is metabolized, which accounts, in part, for the increased hepatotoxicity observed with this agent.

Chemical Properties

Clear, colourless, mobile, heavy, non-flammable liquid

Chemical Properties

Halothane is a highly volatile, nonflammable, colorless liquid. Sweet odor.

Originator

Fluothane,Ayerst,US,1958

Uses

2-Bromo-2-chloro-1,1,1-trifluoroethane, or halothane, has been used in a study that combined molecular simulations with free energy simulations to study solvation of halothane in polarizable water and methanol. Halothane has also been used in a study to investigate the interaction of anesthetics with the Rho GTPase regulator Rho GDP dissociation inhibitor.

Uses

depigmentor, antioxidant

Uses

Halothane is used as a clinical anesthetic.

Definition

A colorless nonflammable liquid halocarbon used as a general anesthetic. The systematic name is 1-chloro-1-bromo-2,2,2-trifluoroethane.

Definition

ChEBI: A haloalkane comprising ethane having three flouro substituents at the 1-position as well as bromo- and chloro substituents at the 2-position.

Indications

Because of its potent and rapid effect, halothane (MAC0.77) is used in special vaporizers mixed with oxygen and water. The high lipid – blood partition coefficient leads to considerable accumulation in tissue and fat. Halothane reduces the peripheral vascular resistance, increases the possibility of arrythmias, and has a negative effect on liver function. On repeated use it is hepatotoxic.

Manufacturing Process

According to US Patent 2,849,502, the apparatus used consisted of a 2" x 24" silica tube packed with silica chips and enclosed in a vertical electric furnace. 1,1,1-trifluoro-2-chloroethane as vapor and bromine as liquid were introduced into a narrow tube passing down the inside of the reaction tube. The mixed reactants then passed up through the reaction tube which was maintained at a temperature of about 465°C. The reaction products were passed through a water-cooled condenser which condensed out most of the desired 1,1,1- trifluoro-2-bromo-2-chloroethane along with any high boiling by-products and unchanged bromine.
This condensate was washed with dilute caustic soda solution and dried over calcium chloride. The exit gases from this condenser were scrubbed with water and dilute caustic soda solution, dried and passed to a condenser cooled with a mixture of solid carbon dioxide and trichloroethylene which caused the unchanged 1,1,1-trifluoro-2-chloroethane to condense. This second condensate was then combined with the first and the mixture was fractionally distilled.
During a run of 2 hours 620 grams of 1,1,1-trifluoro-2-chloroethane and 630 grams of bromine were fed to the reactor and the product was worked up as described above. On fractional distillation there was obtained a first cut up to 50°C consisting of unchanged 1,1,1-trifluoro-2-chloroethane, then a middle cut between 50° and 52°C consisting of substantially pure 1,1,1-trifluoro-2- bromo-chloroethaneand a higher boiling residue that contained a further quantity of the desired product together with some 1,1,1-trifluoro-2,2- dibromo-2-chloroethane. On redistillation of the middle fraction pure 1,1,1- trifluoro-2-bromo-2-chloroethane was obtained with BP 50° to 50.5°C.

brand name

Fluothane (Wyeth).

Therapeutic Function

Inhalation anesthetic

Biological Functions

Halothane (Fluothane) depresses respiratory function, leading to decreased tidal volume and an increased rate of ventilation. Since the increased rate does not adequately compensate for the decrease in tidal volume, minute ventilation will be reduced; plasma PaCO₂ rises, and hypoxic drive is depressed.With surgical anesthesia, spontaneous ventilation is inadequate, and the patient’s ventilation must be controlled.
Halothane administration can result in a marked reduction in arterial blood pressure that is due primarily to direct myocardial depression, which reduces cardiac output. The fall in pressure is not opposed by reflex sympathetic activation, however, since halothane also blunts baroreceptor and carotid reflexes. Systemic vascular resistance is unchanged, although blood flow to various tissues is redistributed. Halothane also sensitizes the heart to the arrhythmogenic effect of catecholamines. Thus, maintenance of the patient’s blood pressure with epinephrine must be done cautiously.

General Description

Clear colorless highly volatile liquid with a sweet chloroform-like odor . Density 1.875 g / cm3. Boiling point 122.4°F (50.2°C). Noncombustible.

General Description

Halothane is a nonflammable, nonpungent, volatile, liquid,halogenated (F, Cl, and Br) ethane (bp＝50°C), introducedin 1956. Halothane may increase heart rate, cause cardiacarrhythmias, increase cerebral blood flow, and increase intracranialpressure.It can undergo spontaneous oxidationwhen exposed to ultraviolet light to yield HCl, HBr, Cl ,Br^- , and phosgene (COCl₂). To prevent oxidation it ispackaged in amber bottles with a low concentration of thymol(0.01%) as a stabilizer. The drug has a high potency(MAC＝0.75%), a blood:gas partition coefficient of 2.4,and high adipose solubility. Halothane undergoes both reductiveand oxidative processes with up to 20% of the doseundergoing metabolism .The trifluoroacetylchloride metabolite is electrophilic and can form covalentbonds with proteins leading to immune responses andhalothane hepatitis upon subsequent halothane exposure.Halothane hepatitis is rare with 1 case reported for every6,000 to 35,000 patients exposed.

Air & Water Reactions

Slightly water soluble.

Reactivity Profile

2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE is sensitive to exposure to light. Incompatible with oxidizing materials. Tarnishes or corrodes most metals, with the exception of chromium, nickel and titanium. When moisture is present, 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE attacks aluminum, brass and lead, but not copper. Contact causes rubber and some plastics to deteriorate rapidly.

Health Hazard

Health hazard may arise from exposure tohigh concentrations of vapors. The target sites are the central nervous system, car diovascular system, and liver. The toxiceffects include depression of the central ner vous system, nausea, vomiting, increasedbody temperature, excitability, arrhythmias,vasodilatation, hepatitis, and liver necrosis.An anesthetic effect in humans is noted atan exposure level of 10,000 ppm. Repeatedexposure to halothane at anesthetic concen trations may result in hepatic lesions andnecrosis. Contact of liquid with the eyes mayresult in severe irritation. The lethal con centration in humans for a 3-hour exposureperiod is in the range of 7000 ppm.
LC50 value, inhalation (mice): 22,000 ppm/10 min
LD50 value, oral (guinea pigs): 6000 mg/kg
No mutagenic effect was observed. Carcino genicity in animals has not been reported.

Fire Hazard

Literature sources indicate that 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE is nonflammable.

Biochem/physiol Actions

Inhalation anesthetic. In an effect believed to be independent of anesthesia, halothane inhibits synthesis of 5-hydroxytryptamine in brain tissue, probably at the tryptophan hydroxylase step.

Clinical Use

The use of inhaled anesthetics and halothane in particularcan produce malignant hyperthermia (MH) in geneticallysusceptible individuals. This results in an increase inbody temperature, tachycardia, tachypnea, acidosis, andrhabdomylolysis. MH is a result of the excessive release ofcalcium from the sarcoplasmic reticulum (SR). Patientswith an inherited mutation in the ryanodine receptor(RYR1), which is located in the SR, are at an increased riskof developing MH when exposed to an inhaled anesthetictriggering agent. Treatment entails discontinuing the anestheticagent, rapid cooling, intravenous dantrolene sodium,and supportive measures. MH has been reported to occurwith all anesthetics agents and with succinylcholine, a depolarizingneuromuscular blocker. The combination ofhalothane and succinylcholine appears to trigger a great extentof the MH episodes. Patients with a family history ofMH can be genetically screened for MH susceptibility viathe caffeine–halothane contracture test. This test is invasiverequiring a piece of skeletal muscle to conduct and it isexpensive costing approximately $5,000 (cost in 2008).Noninvasive molecular genetic screening is currently beingdeveloped.

Synthesis

Halothane is manufactured by chlorination of CF3CH2Br or bromination of CF3CH2Cl in the gas phase at 250 – 475 ?C or by the rearrangement .

Potential Exposure

Halothane is used as an inhalation anesthetic. It has been estimated that halothane accounts for two-thirds of all anesthetics.

Veterinary Drugs and Treatments

Halothane remains a useful general anesthetic in veterinary medicine due to its relative safety, potency, controllability, non-flammability, and comparatively low cost. However, its use has been largely supplanted by newer agents such as isoflurane and sevoflurane that have less cardiodepressant effects.

First aid

If this chemical gets into the eyes, remove anycontact lenses at once and irrigate immediately for at least15 min, occasionally lifting upper and lower lids. Seek med-ical attention immediately. If this chemical contacts theskin, remove contaminated clothingand wash immediatelywith soap and water. Seek medical attention immediately.If this chemical has been inhaled, remove from exposure,begin rescue breathing (using universal precautions, includ-ing resuscitation mask) if breathing has stopped and CPR ifheart action has stopped. Transfer promptly to a medicalfacility. When this chemical has been swallowed, get medi-cal attention. Give large quantities of water and induce :vomiting. Do not make an unconscious person vomit.

storage

Color Code- Green: General storage may be used.Prior to working with this chemical you should be trainedon its proper handling and storage. Store in tightly closedcontainers in a dark, cool, well-ventilated area, away fromdirect sunlight, oxidizers.

Shipping

UN3082 Environmentally hazardous substances, liquid, n.o.s., Hazard class: 9; Labels: 9-Miscellaneous haz ardous material, Technical Name Required.

Incompatibilities

May attack rubber and some plastics; sensitive to light. Light causes decomposition. May be stabilized with 0.01% thymol. Halothane is incompatible with oxidizers (chlorates, nitrates, peroxides, permanga nates, perchlorates, chlorine, bromine, fluorine, etc.); con tact may cause fires or explosions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, epoxides. Tarnishes or corrodes most metals, with the exception of copper, chromium, nickel, and titanium. Attacks aluminum, brass and lead in the presence of moisture. Attacks rubber and causes some plastics to deteriorate rapidly.

Waste Disposal

The compound is mixed with a combustiblesolvent and burned in a chemical incineratorequipped with an afterburner and scrubber.

Halothane(151-67-7)Related Product Information

• methoxyflurane
• 1,1,1,2,3,3,3-Heptafluoropropane
• 2-bromo-1-chloro-1,2,2-trifluoroethan
• Sevoflurane
• DIBROMODIFLUOROMETHANE
• Fluoxetine
• Isoflurane
• Enflurane
• 1,2-DICHLOROTETRAFLUOROETHANE
• 1,1,1,2-Tetrafluoroethane
• 1-CHLORO-1,1-DIBROMO-2,2,2-TRIFLUOROETHANE
• Halothane
• FLUOROETHANE
• 2-BROMO-1,1,1-TRIFLUOROETHANE
• 2-CHLORO-1,1,1-TRIFLUOROETHANE
• Bromoethane
• 1,1,1-Trifluoroethane
• 2,3-DIBROMO-2-CHLORO-1,1,1,4,4,4-HEXAFLUOROBUTANE